Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

wance was made after the Company determined that it was more likely than not that these deferred tax assets would be realized.  Due to the release of the valuation allowance in 2012, starting in 2013, the Company has recorded income taxes on GAAP income using an estimated effective tax rate. Non-GAAP net income excludes non-cash income tax expense.  The Company does not currently pay, or expect to pay in the near future, significant cash income taxes. 

Non-GAAP and GAAP Net Income: The Company reported non-GAAP net income of $201 million, or $2.07 per basic share and $1.78 per diluted share, in the first quarter of 2013, compared to non-GAAP net income of $40 million, or $0.43 per basic share and $0.37 per diluted share, in the first quarter of 2012.  Non-GAAP net income excludes non-cash share-based compensation expense, non-cash interest expense related to the convertible senior notes, and non-cash income tax expense. 

The Company reported GAAP net income of $99 million, or $1.02 per basic share and $0.90 per diluted share, in the first quarter of 2013, compared to GAAP net income of $12 million, or $0.12 per basic share and $0.11 per diluted share, in the first quarter of 2012. 

Cash Position: At March 31, 2013, cash and marketable securities totaled $663 million (including $8 million of restricted cash and marketable securities), compared to $588 million (including $8 million of restricted cash and marketable securities) at December 31, 2012.  In addition, accounts receivable related to sales of EYLEA totaled $702 million at March 31, 2013, compared to $592 million at December 31, 2012.

Use of Non-GAAP Financial Measures: The Company believes that the presentation of non-GAAP measures is useful to investors because it excludes (i) non-cash share-based compensation expense which fluctuates from period to period based on factors that are not within the Company's control, such as the Company's stock
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Regeneron Announces March 2012 Investor Conference Presentations
5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... New applications of structures and materials that ... nature over millennia are featured in a special ... in biophotonics in the October issue of the ... by SPIE, the international society for optics and photonics, ... articles are accessible via open access. , “Biomimetic and ...
(Date:10/1/2014)... 2014 Slone Partners , a ... IT, and Laboratory Testing industries, reported a 120% increase ... director level and above from July 2013 to July ... top of rapid breakthroughs in diagnostics, reimbursement has failed ... have been forced to fold, consolidate, or carry on ...
(Date:10/1/2014)... Ill. (PRWEB) October 01, 2014 The ... $9,956,011 to Southern Illinois University Edwardsville as part of ... (TAACCCT) initiative. The funding is co-administered by the Department ... Joe Biden, Secretary of Labor Thomas E. Perez and ... $450 million in job-driven training grants to nearly 270 ...
(Date:10/1/2014)... PHILADELPHIA , October 1, 2014 ... plans to software invited to engage around the theme, ... 29-30     Elsevier ... information products and services, will host a gathering of ... discuss issues and trends impacting healthcare today and in ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Live Webcast and Conference Call Scheduled for Monday, March 31st at 5 PM ... ... 26 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced that the Company ... Monday, March 31,2008, at 5:00 p.m. ET to discuss corporate updates and financial ...
... the Largest Sales Teams Promoting a 5-ASA ... 26 /PRNewswire-FirstCall/,-- Shire plc (LSE: SHP, NASDAQ: ... a co-promotion agreement with,TAP Pharmaceutical Products Inc. ... the induction of remission in patients with,active, ...
... March 26 Thomas W. Burke, MD, Executive ... M.D. Anderson,Cancer Center, has been elected the 40th ... the organization,s 39th Annual Meeting,held March 9-12, 2008 ... undergraduate and medical degrees from Tulane,University in New ...
Cached Biology Technology:Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 2Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 3Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 4Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 5Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 2Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 3
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... German . ... risky situations such as exposure to predators. Researchers from ... a long-term study on different populations of great tits ... ambient temperature. High metabolic rates and low temperatures were ... birds were more likely to approach potential predators. , ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... In the five months since passage of the ... of research-related awards have been made, supporting important scientific ... increase in basic research funding in American history - ... scientific research and education projects, while $3.5 billion is ...
... 30, 2009) A team of 80 researchers from ... Shifting Sands: Environmental and Cultural Change in Maryland,s Coastal ... barrier islands making up Maryland,s Atlantic coastline. Published ... the history, setting, context and ecology of these waterways, ...
... from the talents of Rembrandt, Van Gogh and other ... of colors on a palette. In a similar manner, ... (NIST) have created an innovative device called the "microfluidic ... concentration across an areain a miniature chamber about the ...
Cached Biology News:'Microfluidic palette' may paint clearer picture of biological processes 2
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Biology Products: